Evonik has announced a partnership with global antibody expression specialist evitria as it looks to accelerate its early biologics development. The collaboration is set to advance a transient protein expression kit based on CHO cells for biopharmaceutical research and development. Evonik says the kit is designed to enable faster, more reliable, and scalable protein production. CHO […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!